On Thursday, Shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX), lost -6.51% to $67.68.
Eagle Pharmaceuticals, declared that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will each present at two conferences in November as follows:
- Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 9:30 a.m. EST in New York Palace, NYC.
- Jefferies Autumn 2015 Global Healthcare Conference on Thursday, November 19, 2015 at 8:40 a.m. GMT in The May Fair Hotel, London
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.
Shares of Rig Net Inc (NASDAQ:RNET), declined -5.90% to $19.93, during its last trading session.
RigNet, stated quarterly results for the quarter ended September 30, 2015.
Quarterly revenue was $66.3 million, representing decreases of $21.5 million, or 24.5%, and $8.8 million, or 11.7%, respectively, as contrast to the preceding year and preceding quarters. Telecoms Systems Integration contributed $8.2 million and $4.9 million, respectively, to the revenue decline as contrast to the preceding year and priority quarters, primarily as a result of reduced activity and backlog. Managed Services revenue reduced $13.3 million and $3.9 million, respectively, as contrast to the preceding year and priority quarters, primarily due to reduced spending by oil and gas operators on upstream drilling projects as a result of lower commodity prices.
Quarterly Adjusted EBITDA was $14.5 million, or 21.9% of revenue, representing decreases of $5.7 million, or 28.2%, and $4.0 million, or 21.7%, respectively, over the preceding year and preceding quarters. These decreases resulted primarily from lower revenue partially offset by benefits from cost containment actions.
Quarterly Cash Earnings were $12.2 million, or $0.69 per diluted share, representing decreases of $2.6 million, or 17.7%, and $3.2 million, or 20.5%, respectively, over the preceding year and preceding quarters.
Capital expenditures were $6.1 million contrast to $10.0 million in the preceding year quarter. Unlevered Free Cash Flow, defined as Adjusted EBITDA less capital expenditures, was $8.4 million, a decrease of $1.8 million, or 17.6%, over the preceding year quarter.
RigNet, Inc. provides digital technology solutions to the oil and gas industry. The company operates through three segments: Eastern Hemisphere, Western Hemisphere, and Telecoms Systems Integration.
Finally, Shares of Medici Nova, Inc. (NASDAQ:MNOV), ended its last trade with -10.18% loss, and closed at $3.00.
Medici Nova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), recently declared that it has received a Notice of Allowance from the Japan Patent Office of MN-221 (bedoradrine) for the treatment of irritable bowel syndrome.
Once issued, the patent maturing from this allowed patent application is predictable to expire no earlier than April 2031. The allowed claims cover a compound, pharmaceutical composition and a method of treating irritable bowel syndrome. Medici Nova intends to use bedoradrine in future development.
“We are very happy that this new patent will be granted as we believe it could substantially improvement the potential value of MN-221,” commented Yuichi Iwaki, MD, PhD, President and CEO of Medici Nova, Inc.
“This is an opportunity to allow us more flexibility to consider pursuing other indications for MN-221 in future development.”
Medici Nova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market.